U.S. patent application number 13/041204 was filed with the patent office on 2011-07-21 for janus family kinases and identification of immune modulators.
This patent application is currently assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT., OF HEALTH & HUMAN SERVICES. Invention is credited to James A. Johnston, Masaru Kawamura, Warren J. Leonard, Daniel W. McVicar, John J. O'Shea, Sarah M. Russell.
Application Number | 20110177526 13/041204 |
Document ID | / |
Family ID | 35449197 |
Filed Date | 2011-07-21 |
United States Patent
Application |
20110177526 |
Kind Code |
A1 |
O'Shea; John J. ; et
al. |
July 21, 2011 |
JANUS FAMILY KINASES AND IDENTIFICATION OF IMMUNE MODULATORS
Abstract
An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein
is a protein tyrosine kinase having a molecular weight of
approximately 125 kDa which has tandem non-identical catalytic
domains, lacks SH2 or SH3 domains, and is expressed in NK cells and
stimulated or transformed T cells, but not in resting T cells. The
protein itself and antibodies to this protein are also presented.
Further, methods of identifying therapeutic agents for modulating
the immune system make use of the foregoing.
Inventors: |
O'Shea; John J.; (Silver
Spring, MD) ; Leonard; Warren J.; (Bethesda, MD)
; Johnston; James A.; (Belfast, IE) ; Russell;
Sarah M.; (East Melbourne, AU) ; McVicar; Daniel
W.; (Charles Town, WV) ; Kawamura; Masaru;
(Rockville, MD) |
Assignee: |
THE UNITED STATES OF AMERICA, AS
REPRESENTED BY THE SECRETARY, DEPT., OF HEALTH & HUMAN
SERVICES
BETHESDA
MD
|
Family ID: |
35449197 |
Appl. No.: |
13/041204 |
Filed: |
March 4, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12354668 |
Jan 15, 2009 |
7902348 |
|
|
13041204 |
|
|
|
|
11195197 |
Aug 1, 2005 |
7488808 |
|
|
12354668 |
|
|
|
|
08373934 |
Jan 13, 1995 |
7070972 |
|
|
11195197 |
|
|
|
|
Current U.S.
Class: |
435/7.8 ; 435/15;
435/7.1 |
Current CPC
Class: |
C12N 9/1205 20130101;
A61K 48/00 20130101; C07K 16/40 20130101 |
Class at
Publication: |
435/7.8 ; 435/15;
435/7.1 |
International
Class: |
G01N 33/68 20060101
G01N033/68; C12Q 1/48 20060101 C12Q001/48 |
Claims
1. A method of identifying an agent having immunomodulating
activity, comprising: determining the ability of the IL-2 receptor
.beta. or .gamma..sub.c chain to physically associate with a Janus
family kinase selected from the group consisting of JAK-1 and JAK-3
in the absence of a candidate agent; and determining the ability of
said chain of IL-2 receptor to physically associate with said Janus
family kinase in the presence of said candidate agent; wherein a
lesser or greater ability to associate in the presence of said
agent indicates immunomodulating activity.
2. The method of claim 1, wherein each of the determining steps is
performed in the presence of a cytokine compound.
3. The method of claim 2, wherein said cytokine compound is a
cytokine compound that binds to a receptor including .gamma.
chain.
4. The method of claim 3, wherein said cytokine compound is
selected from the group consisting of IL-2, IL-4, IL-7, IL-9 and
IL-15.
5. The method of claim 1, wherein each of the determining steps
comprises immunoprecipitating said chain of IL-2 receptor with an
antibody specific to said chain and determining if said Janus
family kinase coprecipitates with said chain.
6. The method of claim 1, wherein said candidate agent is a peptide
fragment of said .gamma..sub.c chain of IL-2.
7. A method of identifying a therapeutic agent for modulating the
immune system, comprising: isolating a Janus family kinase selected
from the group consisting of JAK-1 and JAK-3; determining the
ability of said kinase to phosphorylate a substrate therefor in the
absence of a candidate agent; and determining the ability of said
kinase to phosphorylate said substrate in the presence of said
candidate agent; wherein a decrease in the ability of said kinase
to phosphorylate said substrate in the presence of said candidate
agent indicates that said candidate agent is an immunosuppressive
agent, and wherein a greater ability of said kinase to
phosphorylate said substrate in the presence of said candidate
agent indicates that said candidate agent is an immuno-enhancing
agent.
8. The method of claim 7, wherein the isolating step comprises
immunoprecipitating said Janus family kinase with an antibody
specific to said Janus family kinase.
9. The method of claim 7, wherein each of the determining steps
comprises: reacting said Janus family kinase with .gamma.-labeled
ATP to produce reaction products; separating said reaction products
by electrophoresis; and identifying labeled products.
10. The method of claim 7, wherein each of the determining steps
comprises: reacting said Janus family kinase with ATP to produce
reaction products; separating said reaction products by
electrophoresis; exposing the separated reaction products to an
antibody specific to phosphotyrosine; and identifying reaction
products that exhibit binding to said antibody.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 12/354,668, filed Jan. 15, 2009, which is a divisional of
11/195,197, filed Aug. 1, 2005 (now U.S. Pat. No. 7,488,808, issued
Feb. 10, 2009), which is a continuation of U.S. application Ser.
No. 08/373,934, filed Jan. 13, 1995 (now U.S. Pat. No. 7,070,972,
issued Jul. 4, 2006), each of which is hereby expressly
incorporated by reference in their entireties.
SEQUENCE LISTING
[0002] Incorporated by reference herein in its entirety is the
Sequence Listing filed in the parent application, U.S. patent
application Ser. No. 12/354,668, filed Jan. 15, 2009 with the U.S.
Patent and Trademark Office, size of 27 kilobytes.
FIELD OF THE INVENTION
[0003] The present invention relates generally to the field of
transmembrane signal transduction. More specifically, the invention
relates to the components of multisubunit receptors for cytokines,
and assays for detecting interactions between these components.
BACKGROUND OF THE INVENTION
[0004] Protein tyrosine kinases (PTK) are critical enzymes for
receptor-mediated signal transduction in lymphocytes. Indeed,
protein tyrosine phosphorylation is an early and requisite event in
signaling for both multichain immune recognition receptors such as
the T-cell antigen receptor (TCR) and cytokine receptors. Unlike
growth factor receptors, neither the TCR nor the cytokine receptors
have intrinsic PTK activity. Rather, they are coupled to
nonreceptor tyrosine kinases. For example, the src family PTK, Lck
and Fyn have been implicated in TCR-mediated signaling. The non-src
family PTK Zap-70 has been shown to associate with the TCR upon
activation. The src family PTK, Lck, Fyn and Lyn have also been
implicated in Interleukin-2 (IL-2) receptor mediated signaling.
[0005] The Janus family kinases (JAKs) represent a recently
described family of PTK. These kinases, called JAK-1, JAK-2 and
Tyk-2, are structurally quite distinct in that they possess tandem
nonidentical catalytic domains. These PTK are ubiquitously
expressed and have been shown to participate in signaling by a
number of cytokine and hormone receptors. These PTK are believed to
exert their effects through tyrosyl phosphorylated transcription
factors.
[0006] IL-2 is a T-cell lymphokine that both functions as a potent
autocrine growth factor and activates other cells, including
B-cells and natural killer (NK) cells. In addition, the interaction
of IL-2 with high affinity IL-2 receptors regulates the magnitude
and duration of the normal T-cell immune response.
[0007] High affinity IL-2 receptors comprise three receptor
components, denoted the IL-2 receptor .alpha., .beta. and the
common .gamma. (.gamma..sub.c) chain. Interestingly, the
.gamma..sub.c chain is a receptor component that is shared by the
receptors for several of the interleukins. In the mechanism of IL-2
signal transduction, IL-2 binding induces heterodimerization of the
cytoplasmic domains of .beta. and .gamma..sub.c. This
heterodimerization is required for IL-2 signaling.
[0008] While the IL-2 receptor is a multi-subunit complex that
lacks intrinsic enzymatic activity, it is clear that protein
tyrosine phosphorylation is an early biochemical step that follows
ligand binding. Occupancy of the IL-2 receptor additionally
stimulates alkalinization of T-cells via Na.sup.+/H.sup.+ exchange,
activation of Ras, Raf and ERK1, induction of the fos, jun and myc
proto-oncogenes, as well as induction of effector functions such as
cytotoxicity and cellular proliferation.
SUMMARY OF THE INVENTION
[0009] One aspect of the invention provides an isolated
polynucleotide encoding the JAK-3 protein. The JAK-3 protein is a
protein tyrosine kinase that has a molecular weight of
approximately 125 kDa. In addition, the JAK-3 protein is
characterized by tandem non-identical catalytic domains. The JAK-3
protein lacks SH2 or SH3 domains, and is expressed in NK cells and
stimulated or transformed T-cells, but not substantially expressed
in resting T-cells. In a preferred embodiment, the isolated
polynucleotide encoding the JAK-3 protein has the nucleotide
sequence of SEQ ID NO:8.
[0010] A second aspect of the invention relates to an isolated
JAK-3 protein. The JAK-3 protein is a protein tyrosine kinase
having a molecular weight of approximately 125 kDa, has tandem
non-identical catalytic domains, lacks SH2 or SH3 domains, and is
expressed in NK cells and stimulated or transformed T-cells, but
not substantially expressed in resting T-cells. In a preferred
embodiment, the isolated JAK-3 protein has the polypeptide sequence
of SEQ ID NO:9.
[0011] A third aspect of the invention relates to an antibody that
is specific to JAK-3 protein. As described above, the JAK-3 protein
is a protein tyrosine kinase having a molecular weight of
approximately 125 kDa. The JAK-3 protein recognized by the claimed
antibody has tandem non-identical catalytic domains, lacks SH2 or
SH3 domains, and is expressed in NK cells and stimulated or
transformed T-cells, but not substantially expressed in resting
T-cells. In a preferred embodiment, the antibody that specifically
recognizes the JAK-3 protein is polyclonal.
[0012] A fourth aspect of the invention provides a method of
identifying an agent having immunomodulating activity. This method
includes first determining the ability of the .beta. or
.gamma..sub.c chain of the IL-2 receptor to physically associate
with a Janus family kinase selected from the group consisting of
JAK-1 and JAK-3 in the absence of a candidate immunomodulatory
agent. A second step includes determining the ability of a chain of
the IL-2 receptor to physically associate with a Janus family
kinase in the presence of the candidate immunomodulating agent. If
the candidate immnomodulating agent causes either a lesser or
greater ability of the IL-2 receptor chain and the Janus family
kinase to associate with each other, then such an ability will
indicate that the candidate agent has immunomodulating activity. In
a preferred embodiment, the two determining steps are performed in
the presence of a cytokine compound. In a more preferred
embodiment, the cytokine compound is a cytokine compound that binds
to a receptor that includes the .gamma..sub.c chain. In yet a more
preferred embodiment, the cytokine compound is selected from the
group consisting of IL-2, IL-4, IL-7, IL-9 and IL-15. In another
preferred embodiment, each of the determining steps includes
immunoprecipitating a chain of the IL-2 receptor with an antibody
that is specific to that chain, and then determining if the Janus
family kinase coprecipitates with that receptor chain. According to
this embodiment, the candidate agent can be a peptide fragment of
the .gamma..sub.c chain of the IL-2 receptor.
[0013] A fifth aspect of the invention relates to a method of
identifying a therapeutic agent for modulating the immune system.
This method includes first isolating a Janus family kinase selected
from the group consisting of JAK-1 and JAK-3. A subsequent step
involves determining the ability of the kinase to phosphorylate a
substrate in the absence of a candidate agent, and then determining
the ability of the kinase to phosphorylate the substrate in the
presence of the candidate agent. A decrease in the ability of the
kinase to phosphorylate the substrate in the presence of the
candidate agent indicates that said candidate agent is an
immunosuppressive agent. Alternatively, a greater ability of the
kinase to phosphorylate the substrate in the presence of the
candidate agent indicates that said candidate agent is an
immuno-enhancing agent. In a preferred embodiment, the isolating
step includes immunoprecipitating the Janus family kinase with an
antibody specific to the Janus family kinase. In a more preferred
embodiment, each of the determining steps includes first reacting
the Janus family kinase with .gamma.-labeled ATP to produce
reaction products, and then separating the reaction products by
electrophoresis and identifying the labeled products. In an even
more preferred embodiment, each of the determining steps includes
first reacting the Janus family kinase with ATP to produce reaction
products, then separating the reaction products by electrophoresis,
exposing the separated reaction products to a labeled antibody
specific for phosphotyrosine, and finally identifying the reaction
products that exhibit binding to the antibody.
DETAILED DESCRIPTION OF THE INVENTION
[0014] We have discovered that a novel protein tyrosine kinase
(PTK), called JAK-3, has structural features characteristic of the
Janus family of PTK. Unlike the three other members of this family,
JAK-3 is only expressed in a narrow spectrum of cell types. Whereas
JAK-1, JAK-2 and Tyk2 are broadly expressed, JAK-3 is the first
Janus family member that exhibits limited tissue expression, or
that is induced following cellular activation. In particular, JAK-3
was found to be predominantly expressed in activated human T
lymphocytes and NK cells. We also have observed JAK-3 expression in
IFN-.gamma. activated human peripheral blood monocytes and B-cells.
Based on this pattern of gene expression, we believe that the
function of JAK-3 is related to important signaling pathways in
these cell types. However, we acknowledge that JAK-3 could also be
inducible in nonhematopoietic tissues by appropriate stimuli.
[0015] Herein we disclose that IL-2 can rapidly induce activation
and tyrosine phosphorylation of JAK-3 in responsive cells.
Additionally, we show that JAK-1, although less prominently
tyrosine-phosphorylated, also is involved in IL-2 receptor
signaling. The data presented below indicate that both JAK-3 and
JAK-1 play important roles in lymphoid activation via the IL-2
receptor. Specifically, JAK-3 and JAK-1 associate with other
components of the IL-2 receptor to form an activated receptor
complex. Thus, agents that inhibit the interaction of either JAK-1
or JAK-3 with other components of the receptor are considered as
candidates for immunomodulatory drugs. We contemplate that such
immunomodulatory drugs can be either immunosuppressing or
immunoenhancing.
[0016] More specifically, compounds that inhibit the interaction of
JAK-1 with IL-2R.beta., or the interaction of JAK-3 with the
.gamma..sub.c subunit of the IL-2 receptor complex are expected to
inhibit IL-2 dependent signal transduction. These inhibitory
compounds can act through mechanisms involving drug interaction
with the kinase, or with the receptor substrate. In the first
instance, the compound may interact with the kinase such that the
kinase fails to phosphorylate the receptor chain. Alternatively,
the inhibitor may act on the kinase such that it fails to
autophosphorylate. According to another contemplated mechanism, the
inhibitory compound may interact with one of the chains of a
multisubunit receptor, so that interaction with the Janus family
kinase is inhibited. Finally, we contemplate compounds which
disrupt the binding between one receptor chain and the Janus family
kinase that ordinarily binds to that receptor subunit.
[0017] The development of assays for identifying compounds that
inhibit IL-2 dependent signalling represents an important step
toward the discovery of novel immunomodulators. Compounds having
inhibitor activity in such assays will be identified as potential
therapeutics for the treatment of autoimmune diseases and
transplant rejection. Autoimmune diseases anticipated as objects of
therapy using drugs identified according to the assays disclosed
herein include, but are not limited to, rheumatoid arthritis,
psoriatic arthritis, lupus and vasculitis. Certain of the drugs
identified according to the present invention are likely to be
useful not only in the treatment of disorders resulting from
inappropriate activation of the IL-2 receptor, but also from
inappropriate activation of other cytokine receptors that share
common subunits with the IL-2 receptor.
[0018] Our approach to the development of an assay for compounds
that inhibit IL-2 dependent signalling stems from our understanding
of the detailed structure of the IL-2 receptor complex. In
particular, we have discovered that two different Janus family
tyrosine kinases interact with different subunits of the IL-2
receptor. Binding of the JAKs to the receptor subunits represents a
critical step in the cytokine signalling pathway. It follows that
any agent that disrupts or prevents this binding will also inhibit
IL-2 dependent signalling. Thus, we have designed an assay to
identify compounds that inhibit interactions between components of
the IL-2 receptor complex as a method for identifying candidate
agents for modulating the immune system.
[0019] Direct physical interactions of IL-2R.beta. with JAK-1 and
.gamma..sub.c with JAK-3 were demonstrated during the development
of the present invention. IL-2 increased JAK-3 association with the
IL-2 receptor, with an apparent increase of .gamma..sub.c-JAK-3
association and de novo induction of IL-2R.beta.-JAK-3 interaction.
Truncation of .gamma..sub.c resulted in its failure to associate
with JAK-3. Moreover, a patient having a mild form of X-linked
combined immunodefficiency (XCID) that was characterized by
diminished IL-2 induced proliferation had a .gamma..sub.c point
mutation (Leu 271 changed to Gln) that decreased .gamma..sub.c
association with JAK-3. Thus, .gamma..sub.c mutations, in at least
some XSCID and XCID patients, can inhibit the ability of
.gamma..sub.c to associate with JAK-3. The severity of this
immunodeficiency owes to the fact that .gamma..sub.c is a component
of multiple cytokine receptors.
[0020] Indeed, the sharing of the .gamma..sub.c subunit of the IL-2
receptor by other cytokine receptors, including receptors for IL-4,
IL-7, IL-9 and IL-15, has led us to believe that any compound which
inhibits the cytokine induced binding of JAK-3 to the .gamma..sub.c
chain would also inhibit signalling through the receptors for any
of these cytokines. Thus, we believe that an assay for compounds
that inhibit cytokine induced binding of JAK-3 to the .gamma..sub.c
chain is useful in the discovery of drugs that could be used to
treat autoimmune diseases that are attributable to the activities
of IL-2, IL-4, IL-7, IL-9 and IL-15.
[0021] Although other materials and methods similar or equivalent
to those described herein can be used in the practice or testing of
the present invention, the preferred methods and materials are now
described. General references for methods that can be used to
perform the various PCR and cloning procedures and nucleic acid and
protein blotting procedures described herein can be found in
Molecular Cloning: A Laboratory Manual (Sambrook et al. eds. Cold
Spring Harbor Lab Publ. 1989) and Current Protocols in Molecular
Biology (Ausubel et al. eds., Greene Publishing Associates and
Wiley-Interscience 1987). The disclosures contained in these
publications are hereby incorporated by reference. A description of
the experiments and results that led to the creation of the present
invention follows.
[0022] We employed the PCR approach described by Harpur et al., in
Oncogene 7:1347 (1992) and by Siliciano et al., in Proc. Natl.
Acad. Sci. USA 89:11194 (1992) to amplify novel PTK encoding
sequences expressed in NK cells. The disclosures of these Harpur et
al. and Siliciano et al. references are incorporated by reference.
Briefly, we first prepared cDNA from NK cell mRNA using reverse
transcriptase. We then performed PCR using degenerate
oligonucleotide primers corresponding to conserved motifs in the
catalytic domains of PTK. The forward primers were designed to
correspond to residues in subdomain VI and to exclude src-family
PTK. The reverse primer corresponded to the reverse complement of
the DVWSFG (SEQ ID NO:1) motif (subdomain IX) conserved in a large
number of PTK.
[0023] Example 1 describes the methods used to isolate an amplified
polynucleotide that corresponded to the JAK-3 tyrosine kinase.
EXAMPLE 1
PCR Amplification of a Novel NK Cell Derived Protein Tyrosine
Kinase
[0024] First strand cDNA was prepared from total RNA that had been
isolated from NK cell RNA according to standard methods. The cDNA
prepared in this fashion served as the template in a subsequent PCR
reaction.
[0025] The forward primer used in this PCR reaction was 5'-CCA GCG
GCC GCG T(G/A/T/C)CA (C/T)CG (G/A/T/C)GA (C/T)C T(G/A/T/C)GC-3'
(SEQ ID NO:2) and the reverse primer was 5'-CCA GCG GCC GCC C(G/A)A
A(G/A/T/C/) (G/C) (A/T)CC A(G/A/T/C)A C(G/A)T C-3' (SEQ ID NO:3).
The resulting products were digested with NotI, subcloned and
sequenced. The PCR fragment corresponding to one novel kinase was
isolated, labeled and used to screen several cDNA libraries. Among
the libraries screened were oligo (dT) primed cDNA libraries
derived from PHA stimulated peripheral blood T-cells and the HUT-78
T-cell line (Clonetech, Palo Alto, Calif.) in the .lamda.gtll
cloning vector, a .lamda. ZAP YT library and a .lamda. ZAP library
from PHA activated T-cells. Purified phage DNA was digested and
subcloned into pBLUESCRIPT (Stratagene, La Jolla, Calif.) for
nucleic acid sequencing. Sequence data were manipulated and
analyzed using the programs of the Genetics Computer Group of the
University of Wisconsin and the BLAST program of NCBI.
[0026] For Northern analysis, total RNA from various human tissues
was either purchased from Clonetech (Palo Alto, Calif.) or prepared
from NK cells and T-cells. Northern blotting was carried out
according to standard procedures. Blots were probed with
radiolabeled nucleic acid probes corresponding to the PCR amplified
fragment described above.
[0027] Results indicated that one of the candidate clones isolated
by this method was preferentially expressed in NK and activated
T-cells as an approximately 4.3 kb mRNA.
[0028] Thus, the DNA fragment amplified using kinase-specific
primers exhibited a tissue-specific pattern of mRNA expression. We
therefore proceeded to isolate a cDNA clone that contained the
entire reading frame for the protein that was partly encoded by the
amplified fragment. We have termed this protein "JAK-3."
[0029] Example 2 describes the method used to determine the DNA
sequence of the polynucleotide that encoded the putative
tissue-restricted kinase obtained in Example 1.
EXAMPLE 2
Isolation and Analysis of a Polynucleotide Encoding JAK-3
[0030] The PCR generated fragment from Example 1 was used as a
probe to screen phage cDNA libraries prepared from the NK-like cell
line, YT, PHA-activated T-cells and HUT-78 cells. Approximately
5.times.10.sup.5 plaques from each library were screened to obtain
multiple overlapping clones that generated a polynucleotide
sequence corresponding to a single long open reading frame. SEQ ID
NO:9 provides the predicted amino acid sequence encoded by the NK
cell derived JAK-3 cDNA. We note that a published report by
Kawamura et al. (Proc. Natl. Acad. Sci. USA 91:6374 (1994)) refers
to the JAK-3 protein disclosed herein as "L-JAK." The
polynucleotide sequence encoding the JAK-3 protein has been filed
in GenBank under accession number U09607 and is provided herein as
SEQ ID NO:8.
[0031] The open-reading frame of this polynucleotide sequence
encompasses 3372 nucleotides and is predicted to encode a
polypeptide having 1124 residues. The molecular weight of the
predicted polypeptide is 125,014 Da. This value is roughly
equivalent to, but slightly smaller than, other JAKs. As described
below, this predicted molecular weight is consistent with the
M.sub.r of the polypeptide identified by Western blotting using the
antiserum prepared against JAK-3.
[0032] The predicted protein encoded by the JAK-3 polynucleotide
exhibited structural features characteristic of a PTK, as would
readily be appreciated by one having ordinary skill in the art.
Like other PTK, a catalytic domain is present in the C-terminal
portion of the molecule (subdomains I-XI). This domain begins with
a typical ATP-binding motif at residues 829-834 (subdomain 1) in
which the canonical GXGXXG (SEQ ID NO:4) motif is evident and is
followed by a critical lysine residue in subdomain II (residue
855). Just C-terminal to subdomain VII is a pair of tyrosine
residues following an acidic residue that could represent the
autophosphorylation site. In subdomain VIII, phenylalanine and
tyrosine residues surround the invariant tryptophan residue. We
note that the locations of the subdomains cited herein are
identified by Kawamura et al. in Proc. Natl. Acad. Sci. USA 91:6374
(1994), the disclosure of which is hereby incorporated by
reference. This atypical motif contrasts with the motifs seen in
src and abl related proteins, and growth factor receptors. Notably
though, this motif (FWYAPE) (SEQ ID NO:5) is present in the Janus
family kinases. The Janus family of PTK comprises PTK that have
tandem nonidentical catalytic domains and a large extracatalytic
segment. These structural features of the Janus family of PTK have
been considered by Wilks et al., in Mol. Cell. Biol. 11:2057
(1991), Harpur et al., in Oncogene 7:1347 (1992), and
Firmbach-Kraft et al., in Oncogene 5:1329 (1990). The entire
catalytic domain, termed the JAK homology (JH) 1 domain, comprises
273 amino acids (residues 822 to 1095) and is followed by a unique
C-terminus.
[0033] In addition to a kinase catalytic domain, the predicted
JAK-3 protein has a region N-terminal to the PTK catalytic domain
that also has elements typical of a protein kinase catalytic
domain. This tandem kinase-like (JH-2) domain is a characteristic
feature of the JAKs, and has been described by Harpur et al., in
Oncogene 7:1347 (1992), Firmbach-Kraft et al., in Oncogene 5:1329
(1990), Velazquez et al., in Cell 70:313 (1992), and Argetsinger et
al., Cell 74:237 (1993). Like other Janus family kinases, this
domain in the NK derived JAK-3 protein lacks some standard features
of a PTK catalytic domain. In particular, the JAK-3 protein appears
to lack an autophosphorylation site in subdomain VII.
[0034] The known JAK family PTK have large extracatalytic segments
(JH 3-7 domains) located N-terminal to the kinase (JH1) and
kinase-like (JH2) domains. While motifs corresponding to SH2 or SH3
domains are lacking, there is a motif that Harpur et al., (Oncogene
7:1347 (1992)) suggested to have SH2-like character. This region is
conserved in three of the four family members, including the JAK-3
protein. Immediately N-terminal to this motif is a highly conserved
motif that is a possible tyrosine phosphorylation site (VDGYFRL)
(SEQ ID NO:6). Other areas of striking homology between the novel
JAK-3 protein and other JAKs are also evident in the remaining
domains (JH 5-7).
[0035] The findings presented above indicated the NK-derived
isolate had nearly all of the characteristics of a JAK family PTK.
Protein homology analysis indicated the overall identity of the NK
PTK to the most closely related Janus family member, JAK-2, was
approximately 68%. The fact that a hydrophilicity plot showed no
evidence for a hydrophobic domain suggested that the JAK-3
polynucleotide sequence encoded a non-receptor type PTK.
[0036] Other members of the Janus family of PTK (JAK-1, JAK-2, and
Tyk2) have been shown to be present in a variety of tissues. These
findings have been described by Wilks et al., in Mol. Cell. Biol.
11:2057 (1991), Harpur et al., in Oncogene 7:1347 (1992), and
Firmbach-Kraft et al., in Oncogene 5:1329 (1990). Given this
precedent, we proceeded to determine if JAK-3 was also broadly
expressed across different tissues and cell types. As described
below, we unexpectedly discovered that JAK-3 expression is
tissue-restricted.
[0037] Example 3 describes the methods used to determine the
expression profile for the JAK-3 mRNA.
EXAMPLE 3
Expression of the JAK-3 mRNA
[0038] Total RNA (20 .mu.g) from various human tissues (purchased
from Clonetech), NK cells and T-cells was electrophoresed in
formaldehyde/agarose gels, transferred to membranes and probed with
a radiolabeled cDNA corresponding to the JH1 and JH2 domains of
JAK-3. T-cells were activated with PHA for 24 hours prior to RNA
isolation. NK cells were activated with IL-2 (1,000 units/ml) for
24 hours prior to RNA isolation. Uniform RNA loading in the
different lanes of the Northern blot was confirmed by ethidium
bromide staining and by hybridization with a probe that detected
ribosomal RNA.
[0039] Unexpectedly, and in contrast to other Janus family members,
JAK-3 exhibited a restricted pattern of mRNA expression across
different tissues. In the absence of stimulation, the mRNA was only
detected in NK cells. Notably, activation of NK cells did not alter
the level of JAK-3 mRNA expression. The JAK-3 mRNA was also
detected at high levels in activated NK cells and activated
T-cells. No JAK-3 mRNA was detected in liver, testis, kidney, small
intestine, brain or lung tissues. Hybridization of the same
Northern Filter with a JAK-1 cDNA probe gave evidence for mRNA
expression in all tissues except for small intestine.
Interestingly, while the JAK-3 mRNA was expressed at very low
levels in resting T-cells, the mRNA was induced upon T-cell
activation.
[0040] Various cultured cell lines were also tested for expression
of the JAK-3 mRNA. As expected, our results indicated the JAK-3
mRNA was constitutively expressed in the NK-like YT cell line. As
predicted by studies with peripheral blood T-cells, the JAK-3 mRNA
was not constitutively expressed in the Jurkat T-cell line but was
induced upon activation. Interestingly, we found that JAK-3 mRNA
was constitutively expressed in the HUT-78 transformed T-cell line.
No expression of this gene was detected in a variety of other cell
lines, including the erythroleukemia cell line, K562.
[0041] We next identified a unique portion of the C-terminal region
of the JAK-3 protein and generated a corresponding synthetic
peptide for use as an immunogen. The conclusion regarding protein
sequence uniqueness was based on the results from a
computer-assisted comparison between the JAK-3 amino acid sequence
and all sequences available through the Program Manual for the
Wisconson Package, Version 8, September 1994, Genetics Computer
Group, (575 Science Dr. Madison, Wis. 53711). This search protocol
included searches of the GenBank, GenPept, SwissProt, Brookhaven
and EMBL databases. The synthetic peptide used in our procedures
corresponded to amino acids 1104-1124 of the JAK-3 protein.
[0042] Example 4 describes the immunological methods used to
analyze the JAK-3 protein.
EXAMPLE 4
Identification of the JAK-3 Protein by Metabolic Labeling and
Immunoprecipitation
[0043] A peptide corresponding to the predicted C-terminus of the
JAK-3 protein (amino acids 1104-1124) was synthesized (Multiple
Peptide Systems, San Diego, Calif.), coupled to keyhole limpet
hemocyanin (KLH) with MBS (Pierce, Rockford, Ill.) and used to
immunize rabbits. HUT-78 cells (10.sup.7 cells per point) were
labeled with .sup.35S methionine (0.5 mCi/ml) for 2 hours, washed
with phosphate buffered saline and lysed in buffer containing 1%
TRITON.TM. X-100 detergent (lysis buffer). Postnuclear supernatants
were immunoprecipitated with 10 .mu.l of antiserum prebound to
protein A sepharose washed in buffer containing 0.1% TRITON.TM.
X-100 detergent (wash buffer), eluted and electrophoresed in 8%
polyacrylamide gels that were subsequently fixed, rinsed in
FLUORO-HANCE.TM. fluorographic enhancer (Research Products Inc.,
Mount Prospect, Ill.) and dried for autoradiography.
[0044] For immunoblot analysis, cells were solubilized in lysis
buffer and postnuclear supernatants (approximately 100 .mu.g of
protein) were electrophoresed, transferred to nitrocellulose and
immunoblotted. Filters were blocked, incubated with antiserum
(1:1000), washed and incubated with peroxidase conjugated goat
antirabbit IgG, all according to standard methods well known in the
art. Antibody binding was detected by enhanced chemiluminescence
(ECL) (Amersham Corp.).
[0045] In good agreement with the molecular weight predicted by the
deduced JAK-3 primary structure, analysis of metabolically labeled
HUT-78 cells showed specific immunoprecipitation of a polypeptide
with a M.sub.r of approximately 125 kDa. Immunoblot analysis of
these cells also showed reactivity of the antibody with a protein
of approximately the same mobility in HUT-78. In contrast Jurkat
T-cells expressed minimal levels of this protein. In additional
experiments, the expression of the JAK-3 encoded polypeptide was
found to parallel the expression seen by analysis of mRNA.
Expression of the protein was detected in NK cells, activated
T-cells and in some transformed leukocyte cell lines.
Immunoblotting with preimmune serum or antiserum competed with
cognate peptide versus irrelevant peptide, thus confirming the
specificity of this reactivity.
[0046] The results obtained in Example 4 confirmed that antibodies
raised against a JAK-3 specific synthetic peptide could be used to
immunoprecipitate the JAK-3 protein from cellular lysates. However,
these results provided no insight into the function of the JAK-3
protein. Thus, to ascertain whether the JAK-3 protein had enzymatic
activity, in vitro kinase assays were performed.
[0047] Example 5 describes the in vitro assay used to demonstrate
that immunoprecipitated JAK-3 protein had kinase activity.
EXAMPLE 5
JAK-3 In Vitro Kinase Activity
[0048] Kinase assays were performed as described by Muller et al.,
in Nature 366:129 (1993), and by Watling et al., in Nature 366:166
(1993). According to these procedures, cells were solubilized in
lysis buffer supplemented with 1 mM Na.sub.3VO.sub.4 and 1 mM EDTA.
An antipeptide antiserum was then used to carry out an
immunoprecipitation reaction. Washed immunoprecipitates were
incubated in 50 .mu.l of buffer containing 20 mM Tris, 5 mM
MgCl.sub.2, 5 mM MnCl, .mu.M ATP, and 200 .mu.Ci/ml .sup.32P-ATP
(Amersham Corp.). The reaction was carried out for 15 minutes at
25.degree. C. and was terminated by the addition of ice cold wash
buffer. After washing the beads again, the reaction products were
eluted, electrophoresed and autoradiographed.
[0049] A phosphorylated polypeptide having the expected 125 kDa
molecular weight was evident in immunoprecipitates from NK cells
but not in immunoprecipitates from resting T-cells or untreated
control cells. The phosphorylated residues were resistant to KOH,
consistent with tyrosyl phosphorylation. We concluded that this
tyrosyl phosphorylation likely represented autophosphorylation of
JAK-3.
[0050] Thus, our results indicated the novel JAK-3 protein had both
structural and functional characteristics of a protein tyrosine
kinase related to the Janus family of PTK. In an effort to discern
the role of JAK-3 in cellular physiology, we made a more extensive
investigation into the range of cell types that expressed the JAK-3
protein.
[0051] Example 6 describes the method used to determine the range
of cell types that express JAK-3 protein.
EXAMPLE 6
Expression of the JAK-3 Protein in Activated T-Cells and NK
Cells
[0052] Whole cell lysates from human peripheral blood T-cells
(unstimulated or stimulated for 48 hours with PHA), the transformed
T-cell lines Hut78 and YT, peripheral blood NK cells, the NK 3.3
cell line, human peripheral blood monocytes, the myelomonocytic
cell lines U937 and THP-1, and the tumor cell line OVCAR-3, HT-29
and IM-9 were run on SDS-PAGE and were probed with antisera to
JAK-3. Human peripheral blood T lymphocytes, NK cells and monocytes
(>97% pure) were obtained by leukophoresis and column
purification according to standard procedures. T lymphocytes were
either untreated or treated with PHA (10 .mu.g/ml) and incubated
for 0-48 hours. Cells were grown in RPMI 1640 supplemented with
calf serum. Cells were lysed in buffer containing TRITON.TM. X-100
detergent and clarified lysates (50 .mu.g) were run on SDS PAGE,
transferred to IMMOBILON.TM. membrane and probed with anti-JAK-3
antisera and HRP-conjugated antirabbit immunoglobulin. Immunoblots
were developed with enhanced chemiluminescence (Amersham) using
standard procedures. The anti-JAK-3 antiserum used in these
procedures was raised against a synthetic peptide corresponding to
the C-terminal region of the JAK-3 protein (amino acids 1104-1124),
and has been described by Kawamura et al., in Proc. Natl. Acad.
Sci. USA 91:6374 (1994).
[0053] The results from these procedures indicated that JAK-3 was
expressed only in a limited spectrum of tissue types. It was
strongly expressed in NK cells, the NK cell line NK 3.3, YT cells
and in the transformed T-cell line Hut78 as judged by the presence
of a 125 kDa band on the Western blot. The JAK-3 protein was not
detected in other cell types that were examined. In contrast to the
pattern of JAK-3 protein expression, other JAK family kinases are
known to be expressed in both lymphoid and nonlymphoid cells. While
JAK-3 was expressed at low levels in resting peripheral blood
T-cells, these levels of expression were greatly increased
following activation by either PHA or anti-CD3.
[0054] The induction of the IL-2 gene and IL-2 receptor a chain are
among the critical events that occur during T-cell activation.
These factors have been considered by Taniguchi in Ann. Rev.
Immunol. 4:69 (1988), and by Leonard et al., in Proc. Natl. Acad.
Sci. USA 80:6957 (1983). As the induction of these genes paralleled
the induction of JAK-3, we investigated the possibility that JAK-3
was somehow coupled to the IL-2 receptor. Indeed, in Cell 74:587
(1993), Stahl et al. disclosed that occupancy of certain other
cytokine receptors induced tyrosine phosphorylation of other
JAKs.
[0055] Example 7 describes the methods used to demonstrate that the
JAK-3 protein is inducibly phosphorylated by IL-2 stimulation of T
and NK cell lines, and peripheral blood NK cells.
EXAMPLE 7
Tyrosine Phosphorylation of JAK-3 in Response to IL-2
[0056] Cells were either unstimulated or stimulated with IL-2 (1000
U/ml) for 5 minutes, then lysed, immunoprecipitated with anti-JAK-3
antisera and immunoblotted and probed with a monoclonal
antiphosphotyrosine antibody (4G10 UBI). In this procedure, cells
were washed twice with RPMI that had been acidified at pH 6.5
before incubation for 3 hours with 0.5% human serum. The cells were
again washed twice before stimulation with IL-2. The cells were
lysed in buffer containing TRITON.TM. X-100 detergent prior to the
immunoprecipitation procedure. Detection of the antiphosphotyrosine
antibody probe bound to the 125 kDa JAK-3 protein band was by
autoradiography.
[0057] Using this procedure, we found that IL-2 induced tyrosine
phosphorylation of JAK-3 in YT (T-cell line) and NK 3.3 (NK cell
line) cells as well as in peripheral blood NK cells. We observed
little basal tyrosine phosphorylation of JAK-3 in any of the cell
samples that were tested. However, after 5 minutes of IL-2
stimulation, intense phosphorylation of a protein band having a
molecular weight of 125 kDa was evident on the autoradiograph. This
band represented the JAK-3 protein. A constitutively expressed
phosphoprotein band that migrated at a discrete position in the gel
between the 69 and 96 kDa molecular weight markers was observed in
YT and NK3.3 cell lines, and in peripheral blood NK cells. A second
constitutive phosphoprotein band was observed in the NK3.3 lanes on
the autoradiograph. In aggregate, these results indicated that
JAK-3 is a protein that is inducibly phosphorylated by stimulation
of T-cells and NK cells with IL-2.
[0058] IL-2 induced tyrosine phosphorylation in the Hut78 T-cell
line was also examined in a time course experiment. Lysates from
Hut78 cells either untreated or treated with IL-2 for 5, 10 or 30
minutes were immunoprecipitated with anti-JAK-3 and blotted with
antiphosphotyrosine antibody and with anti-JAK-3. Our results
indicated that Hut78 cells showed induction of JAK-3 tyrosine
phosphorylation after treatment with IL-2 that was maximal at 10
minutes. Prior absorbance of the JAK-3 antiserum with cognate
peptide eliminated the tyrosine phosphorylated protein at 125 kDa
and thereby confirmed the specificity of the tyrosine
phosphorylated band as JAK-3. JAK-3 was also found to be
phosphorylated in response to IL-2 in human peripheral blood
T-cells that had been pre-activated with PHA for 24 hours. Thus in
human T and NK cells, T-cell and NK cell lines, IL-2 induced the
rapid tyrosyl phosphorylation of JAK-3 protein.
[0059] Both Farrar, et al. (J. Biol. Chem. 264:12,562 (1989)) and
Kirken, et al., (J. Biol Chem. 268:22,765 (1993)) have disclosed
that IL-2 stimulation induced tyrosyl phosphorylation of a variety
of substrates in human peripheral blood T-cells and T-cell lines.
In the following Example, we demonstrated that the most prominent
phosphotyrosyl protein evident following IL-2 stimulation of the YT
cell line was a polypeptide of 125 kDa that comigrated with JAK-3.
To confirm the identity of this 125 kDa substrate as JAK-3, an
experiment was conducted in which lysates from IL-2 treated cells
were first depleted of JAK-3 prior to immunoprecipitation with
antiphosphotyrosine antibodies. In addition, we examined whether
the other JAK family members could be activated by IL-2.
[0060] Example 8 describes the methods used to demonstrate that
JAK-1 and JAK-3 are tyrosine phosphorylated in T-cells upon IL-2
stimulation.
EXAMPLE 8
IL-2 Induced Tyrosyl Phosphorylation of JAK Family Kinases
[0061] Serum-starved YT cells were treated with IL-2 (1000 U/ml)
for 0 or 15 minutes. Cells were lysed in buffer containing
TRITON.TM. X-100 detergent and phosphatase inhibitors and then
immunoprecipitated with an antiphosphotyrosine antibody bound to
protein G sepharose. Lysates were precleared with either rabbit
polyclonal antisera, anti-JAK-3 or anti-JAK-1 before
immunoprecipitation and immunoblotting with anti-phosphotyrosine.
As a positive control to identify the position of JAK-3 on the
Western blot, a sample of the lysate from IL-2 induced cells was
immunoprecipitated with anti-JAK-3 and blotted with
antiphosphotyrosine. All immunoprecipitates were subjected to
SDS-PAGE and transferred to IMMOBILON.TM. membrane.
[0062] Depletion of YT cell lysates with anti-JAK-3 antiserum
specifically removed the 125 kDa tyrosine phosphorylated protein,
thus indicating that JAK-3 was one of the most prominent
phosphoproteins detected in response to IL-2 in these cells.
Conversely, depletion of lysates with anti-JAK-1 did not remove
this phosphoprotein. This result clearly established that JAK-3 is
a prominent tyrosyl phosphoprotein in IL-2 induced T-cells.
[0063] In addition, we examined whether other JAK family members
could be activated by IL-2. An experiment similar to that described
above was performed in which antiphosphotyrosine immunoblots were
purposely overexposed to reveal other substrates. In particular, YT
cells were treated with IL-2 (1000 U/ml) for 0, 5 or 15 minutes,
lysed, immunoprecipitated with anti-phosphotyrosine and
subsequently immunoblotted with anti-phosphotyrosine, and
anti-JAK-3 or anti-JAK-1. We observed a tyrosyl phosphoprotein
induced in response to IL-2 that was larger in size than JAK-3.
Immunoprecipitation with anti-JAK-1 antiserum and immunoblotting
with antiphosphotyrosine confirmed that this protein was JAK-1.
Although both Tyk2 and JAK-2 could be detected in YT cells, no
tyrosyl phosphorylation of either protein was observed in response
to IL-2 stimulation.
[0064] Thus, the results obtained in Example 8 indicated that IL-2
stimulation of T-cells led to tyrosine phosphorylation of JAK-3
and, to a somewhat lesser extent, of JAK-1.
[0065] Example 9 describes the methods used to demonstrate that
IL-2 stimulates JAK-3 in vitro kinase activity.
EXAMPLE 9
IL-2 Stimulates JAK-3 In Vitro Kinase Activity
[0066] Cells were treated with IL-2 (1000 U/ml) for 0, 10 or 20
minutes. In vitro kinase activity was measured in anti-JAK-3
immunoprecipitates. For measurement of in vitro kinase activity,
immunoprecipitates were washed in 50 mM NaCl, 5 mM MgCl.sub.2, 5 mM
MnCl.sub.2, 0.1 mM Na.sub.3VO.sub.4, 10 mM HEPES (pH 7.4) and
incubated in the same buffer containing 0.25 .mu.Ci/ml
[.sup.32P-.gamma.] ATP for 15 minutes at room temperature. After
three washes, proteins were eluted in sample buffer and analyzed by
SDS-PAGE. Gels were either dried or transferred to IMMOBILON.TM.
membrane before exposure. Autophosphorylation signals were detected
by autoradiography of the dried gels. JAK-3 in vitro kinase
activity in response to IL-2 stimulation (15 minutes) was measured
in immunoprecipitates from peripheral blood NK cells and Hut78
cells. JAK-3 immunoprecipitated from YT cells activated in response
to IL-2 displayed elevated kinase activity that peaked at
approximately 10 minutes. Similar results were obtained using human
peripheral blood NK cells and Hut78 cells. This kinase activity was
not precipitated by preimmune serum or in the presence of competing
JAK-3 peptide. These results confirmed that the observed kinase
activity was specific for the JAK-3 protein. The vast majority of
the phosphorylation observed was attributable to phosphorylation of
tyrosine residues as demonstrated by resistance to KOH treatment
and by phosphoamino acid analysis.
[0067] We next examined JAK-3 phosphorylation in YT cells following
stimulation by a number of these cytokines Other members of the JAK
family have been shown to be activated by several lymphokines
including the interferons (IFNs), erythropoietin (EPO), growth
hormone (GH) and IL-3 (Witthuhn et al., Cell 74:227 (1993);
Argetsinger et al., Cell 74:237 (1993); Silvennoinen et al., Proc.
Natl. Acad. Sci. USA 90:8429 (1993)). JAK-3 was tyrosine
phosphorylated in response to IL-2, but not in response to GH,
IFN-.alpha. or IFN-.gamma. in the YT cells. We did detect tyrosine
phosphorylation of JAK-2 in response to IFN-.gamma. in these cells,
thus confirming the activity of this cytokine. Stimulation of YT
cells with IL-3, GM-CSF or EPO also failed to induce JAK-3
phosphorylation. IL-4 has recently been shown to utilize the common
y chain of the IL-2 receptor (.gamma..sub.c), suggesting that
common signaling pathways also may be utilized by these cytokines
(see Russell et al., Science 262:1880 (1993), and Kondo et al.,
Science 262:1874 (1993)). This knowledge prompted us to examine
whether JAK-3 was also activated in response to IL-4.
[0068] Example 10 describes the methods used to test whether other
cytokines, in addition to IL-2, induced JAK-3 tyrosine
phosphorylation.
EXAMPLE 10
Phosphorylation of JAK-3 in Response to Cytokines other than
IL-2
[0069] YT cells were serum-starved for 3 hours and acid washed
twice before stimulation and immunoprecipitation. NK 3.3 cells were
grown for 2 days in 10% lymphocult (Biotest) and 15% fetal bovine
serum before being washed and incubated in 2% serum. Commercial
polyclonal anti-JAK-1 and JAK-2 antisera were obtained from UBI and
Tyk2 polyclonal antiserum from Santa Cruz Biotechnology.
[0070] Lysates of YT cells that were unstimulated or stimulated
with IL-2 (1000 U/ml), GH (50 ng/ml), IFN-.alpha. (1000 U/ml) or
IFN-.gamma. (500 U/ml) for 15 minutes were immunoprecipitated with
anti-JAK-3 and blotted with antiphosphotyrosine. Results from this
Western blotting experiment proved that JAK-3 was tyrosine
phosphorylated in response to IL-2, but not in response to GH,
IFN-.alpha. or IFN-.gamma.. In addition, JAK-3 was not
phosphorylated in response to IL-3, granulocyte macrophage colony
stimulating factor (GM-CSF) or erythropoietin, all of which have
been shown to activate JAK-2.
[0071] In related procedures, NK 3.3 cells that were incubated
overnight in 2% serum were stimulated with IL-2 (1000 U/ml), IL-4
(100 U/ml) or IFN-.gamma. (500 U/ml) for 5 or 15 minutes. Cellular
lysates were immunoprecipitated with anti-JAK-3 and blotted with
antiphosphotyrosine. Results from these procedures indicated that
JAK-3 was tyrosine phosphorylated in response to both IL-4 and IL-2
in NK 3.3 cells. These results confirmed that the JAK-3 kinase is
involved in signaling pathways other than IL-2.
[0072] Given these findings, we proceeded to investigate the
detailed mechanism by which the JAK proteins were involved in IL-2
mediated signal transduction. As described in the following
Examples, we discovered that two of the IL-2 receptor subunits
interacted with the JAKs. In particular, we discovered that the
JAK-1 and JAK-3 proteins physically interacted with the IL-2R.beta.
and .gamma..sub.c IL-2 receptor subunits. Further, the
.gamma..sub.c-JAK-3 binding was found to be induced by IL-2
stimulation. Our procedures began with a demonstration that both
the JAK-1 and JAK-3 proteins are phosphorylated by IL-2
stimulation.
[0073] Example 11 describes methods that can be used to detect
phosphorylation of the JAK-1 and JAK-3 proteins.
EXAMPLE 11
IL-2 Stimulation Induces Phosphorylation of JAK-1 and JAK-3
[0074] Peripheral blood lymphocytes (PBL) were induced for 15
minutes with IL-2 (1000 U/ml), IL-4 (100 U/ml), IL-7 (100 ng/ml),
or IL-9 (100 ng/ml) after phytohemagglutinin (PHA) stimulation. The
PBL were activated for 72 hours with PHA, then washed twice at pH
6.5, incubated for 3 hours in medium containing 0.5% human serum
and resuspended in medium containing 10% fetal calf serum for one
hour. Cells were then lysed and immunoprecipitated with polyclonal
antibodies to JAK-1 (UBI) or JAK-3. The anti-JAK-3 antibody used in
these procedures has been described by Johnston et al., in Nature
370:151 (1994). Phosphotyrosine-containing proteins were detected
by immunoblotting with 4G10 (UBI). NK3.3 cells were stimulated with
IFN-.alpha. (1000 U/ml) or IL-2 (1000 U/ml), immunoprecipitated
with polyclonal antibodies to Tyk2 (UBI) or JAK-2 (UBI) and
immunoblotted with 4G10 mAb to phosphotyrosine (UBI). In one
procedure, the lysate was precleared with polyclonal antibody to
JAK-3.
[0075] Although immunoprecipitation with antibodies to JAK-2
yielded a tyrosine phosphorylated band in response to IL-2, this
band migrated faster than the JAK-2 band induced by
interferon-.gamma. and was human JAK-3, immunoprecipitated through
cross-reactivity with the JAK-2 antiserum. This was demonstrated by
elimination of this band by preclearing the lysate with a JAK-3
specific antiserum. In addition to IL-2, we tested three other
known .gamma..sub.c users, IL-4, IL-7 and IL-9, for their abilities
to induce the tyrosine phosphorylation of JAK-1 and JAK-3. Each of
these cytokines induced tyrosine phosphorylation of both JAK-1 and
JAK-3 in Western blotting procedures and activated both JAK-1 and
JAK-3 as evaluated by in vitro kinase assays. Thus, cytokines that
signal using mechanisms that involve the common .gamma..sub.c
subunit induce phosphorylation of JAK-1 and JAK-3.
[0076] Given the essential roles of both IL-2R.beta. and
.gamma..sub.c in IL-2 signal transduction, we investigated the
ability of each of these chains to physically associate with JAK-1
and/or JAK-3, the two Janus kinases that were activated and
tyrosine phosphorylated in response to IL-2. YT cellular lysates
were immunoprecipitated with Mik.beta.1 (anti-IL-2R.beta.)
monoclonal antibody (mAb) or R878 (anti-.gamma..sub.c) antiserum,
followed by Western blotting with JAK-3 and reblotting with
JAK-1.
[0077] Example 12 describes the methods used to demonstrate that
JAK-1 binds the IL-2R.beta. subunit, and that JAK-3 binds the
.gamma..sub.c subunit of the IL-2 receptor.
EXAMPLE 12
Physical Association of JAK-1 and JAK-3 with Components of the IL-2
Receptor
[0078] YT cells were either stimulated or not stimulated with IL-2
and then lysed with 10 mM Tris (pH 7.5) containing 2 mM EDTA, 0.15
M NaCl, 0.875% Brij 96, 0.125% NONIDET P40.TM. detergent, 0.4 mM
sodium vanadate, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride
hydrochloride (ICN), 2.5 mM leupeptin, 2.5 mM aprotinin.
Immunoprecipitations were performed using Mik.beta.1
anti-IL-2R.beta. mAb, R878 antiserum to .gamma..sub.c, or RPC5
(control mAb). The gel was Western blotted sequentially with
antisera to JAK-3 and then JAK-1 using ECL. The object of this
coprecipitation procedure was to test whether precipitation of one
subunit of the IL-2 receptor would also precipitate one of the JAK
proteins.
[0079] Our results indicated that JAK-1 constitutively associated
with IL-2R.beta., and that the quantitative extent of association
did not increase following IL-2 stimulation. JAK-1 did not
constitutively associate with .gamma..sub.c, but after IL-2
stimulation and the induction of association of IL-2.beta. with
.gamma..sub.c, some JAK-1 coprecipitated with .gamma..sub.c.
Although JAK-3 weakly associated with .gamma..sub.c in the absence
of IL-2, this association increased following IL-2 stimulation.
Moreover, after IL-2 stimulation, JAK-3 was readily coprecipitated
with anti-IL-2R.beta. mAb Mik.beta.1 or TU11. This was expected for
TU11, which binds to an IL-2R.beta. epitope distinct from the IL-2
binding site and coprecipitates .gamma..sub.c in the presence but
not absence of IL-2, but was unexpected for Mik.beta.1, which
competes for IL-2 binding and cannot coprecipitate .gamma..sub.c in
the presence or absence of IL-2.
[0080] These data indicated that IL-2R.beta. primarily associated
with JAK-1 and that .gamma..sub.c associated with JAK-3. However,
interactions between IL-2R.beta. and JAK-3 also occurred. Though
the basis for the IL-2 induced association of IL-2R.beta. with
JAK-3 is unknown, IL-2 induced heterodimerization of IL-2R.beta.
and .gamma..sub.c may juxtapose JAK-3 to IL-2R.beta., thus
facilitating their interaction. Significantly, the association of
JAK-3 with .gamma..sub.c was induced by IL-2.
[0081] To further evaluate the association of IL-2R.beta. and
.gamma..sub.c with JAK-1, we transiently transfected COS-7 cells
with cDNAs encoding JAK-1 and either IL-2R.beta. or
.gamma..sub.c.
[0082] Example 13 describes a cotransfection procedure that
confirmed the physical interaction between JAK-1 and IL-2R.beta..
The results of this procedure did not provide evidence for an
interaction between JAK-1 and the .gamma..sub.c receptor
subunit.
EXAMPLE 13
Recombinant JAK-1 Associates with Recombinant IL-2R.beta. in
Transfected Cells
[0083] Cotransfection of COS-7 cells with JAK-1 and either
IL-2R.beta. or .gamma..sub.c expression constructs was followed by
immunoprecipitation and Western blotting with Erd A antiserum to
IL-2R.beta., R878 antiserum to .gamma..sub.c or antiserum to JAK-1.
The IL-2R.beta. expression construct used in this procedure
consisted of the IL-2R.beta.1 cDNA insert described by Gnarra et
al., in Proc. Natl. Acad. Sci. USA 87:3440 (1990), under
transcriptional control of the SR.alpha. promoter that has been
described by Takebe et al., in Mol. Cell. Biol. 8:466 (1988). The
.gamma..sub.c expression construct used in this procedure included
a .gamma..sub.c cDNA insert derived from a clone that was isolated
from a cDNA library prepared from YT cell mRNA. The 5' end of the
.gamma..sub.c cDNA insert corresponded to position -43 as presented
in FIG. 2 by Noguchi et al., in J. Biol. Chem. 268:13601 (1993),
and extended to the 3' end of the full length .gamma..sub.c
sequence that has been presented by Takeshita et al., in Science
257:379 (1992). The JAK-1 expression construct used in this
procedure had the JAK-1 cDNA under transcriptional control of the
CMV promoter. When JAK-1 and IL-2R.beta. expression constructs were
cotransfected, antibodies to either protein coprecipitated the
other as evaluated by Western blotting. As expected, the RPC5
control mAb failed to immunoprecipitate material that could be
identified by either the anti-JAK-1 or the anti-IL-2R.beta.
antiserum on the Western blot. This negative result confirmed the
specificity of the blotting procedure. The Gnarra et al., Takebe et
al., Noguchi et al., and Takeshita et al. references referred to in
this example are all incorporated herein by reference.
[0084] Our results also indicated that .gamma..sub.c and JAK-1 did
not associate with each other. This latter finding was evidenced by
the inability of anti-JAK-1 to immunoprecipitate material that
could be stained on Western blots probed with anti-.gamma..sub.c
antibodies, and by the inability of anti-.gamma..sub.c to
immunoprecipitate material that could be stained on Western blots
probed with anti-JAK-1. On the other hand, anti-JAK-1
immunoprecipitated material that was stained by anti-JAK-1, and
anti-.gamma..sub.c antibodies immunoprecipitated material that was
stained by anti-.gamma..sub.c antibodies. This latter observation
confirmed the integrity of the reagents used in these procedures.
As expected, the RPC5 control mAb failed to immunoprecipitate
material that was stained by either anti-JAK1 or anti-IL-2R.beta.
antiserum on the Western blot. Although the positive control
procedures confirmed our ability to detect all relevant protein
species, we did not obtain any evidence for an association between
JAK-1 and the .gamma..sub.c receptor chain. However, these findings
did confirm a physical association between JAK-1 and
IL-2R.beta..
[0085] We conducted an experiment to determine the relative
importance of the cytoplasmic domain of the IL-2R.beta. receptor
chain, and to test the importance of the extracellular domain with
respect to facilitating the interaction between JAK-1 and the
IL-2R.beta. chain. COS-7 cells were cotransfected with JAK-1 and
either IL-2R.alpha., chimeric .alpha./.alpha./.beta. or chimeric
.alpha./.gamma./65 expression constructs according to standard
protocols. The structures of the chimeric constructs encoding these
novel receptor chains has been described by Nakamura et al., in
Nature 369:330 (1994), the disclosure of which is hereby
incorporated by reference. The RPC5 control mAb and anti-Tac mAb to
IL-2R.alpha. were separately used for immunoprecipitations that
were followed by Western blotting with antiserum to JAK-1. Neither
anti-Tac nor RPC5 antibodies immunoprecipitated material from
lysates of JAK-1 and IL-2R.alpha. cotransfectants that was also
stained by anti-JAK-1. Thus, there was no evidence that JAK-1
interacted with any portion of the IL-2R.alpha. chain. Neither
anti-Tac nor RPC5 antibodies immunoprecipitated material from
lysates of JAK-1 and chimeric .alpha./.gamma./65 cotransfectants
that was also stained by anti-JAK-1. Thus, there was no evidence
that JAK-1 interacted with the cytoplasmic portion of the
.gamma..sub.c receptor chain. On the other hand, when lysates from
cells cotransfected with JAK-1 and chimeric .alpha./.alpha./62 were
immunoprecipitated with anti-Tac and Western blotted, material
stained by anti-JAK-1 was detected.
[0086] These results established that recombinant components of the
IL-2 receptor associate with each other in defined ways. Further,
our results confirmed the interaction of the JAK-1 and IL-2R.beta.
proteins, and indicated that the cytoplasmic portion of the
IL-2R.beta. chain was required for this interaction.
[0087] We next used transfected COS-7 cells to evaluate the
association of JAK-3 with .gamma..sub.c mutants in order to
identify regions of contact between the JAK-3 and .gamma..sub.c
proteins. These coprecipitation experiments employed two different
anti-.gamma..sub.c antibodies, a monoclonal antibody that
recognized the extracellular domain of .gamma..sub.c, and R878, a
polyclonal antiserum that recognized the intracellular domains of
.gamma..sub.c. As described below, we discovered that recombinant
.gamma..sub.c and JAK-3 proteins efficiently interacted with each
other. In contrast, two truncated forms of the receptor chain in
which either 80 or 48 amino acids had been deleted from the
C-terminus (Russell et al. Science 262:1880 (1993)) exhibited
greatly diminished association with JAK-3. The 48 amino acid
truncation is smaller than the truncation found in the XSCID
patient with the smallest known naturally occurring .gamma..sub.c
truncation (missing 62 amino acids). Other XSCID patients have been
identified with even larger truncations. Thus, the findings
presented below confirmed that the inability of JAK-3 to associate
with .gamma..sub.c would be a characteristic of many XSCID
patients.
[0088] Example 14 describes experiments which demonstrated
recombinant .gamma..sub.c chains that incorporate mutations similar
to those found in XSCID patients cannot efficiently associate with
JAK-1.
EXAMPLE 14
Mutations in Recombinant .gamma..sub.c Chains Disrupt JAK-3
Binding
[0089] COS-7 cells were transfected with JAK-3 and either wild type
.gamma..sub.c or .gamma..sub.c-.DELTA.CT, .gamma..sub.c-.DELTA.SH2,
.gamma..sub.2-L271Q or with the vector control (pME18S). The
.gamma..sub.c expression construct used in these procedures is
described under Example 13. The .gamma..sub.c-.DELTA.CT and
.gamma..sub.c-.DELTA.SH2 constructs were prepared as described by
Russell et al., in Science 262:1880 (1993). The .gamma..sub.c-L271Q
expression construct was prepared by using the pAlter-1 Mutagenesis
Vector system (Promega), and is essentially identical to the wild
type .gamma..sub.c construct, except for mutation of codon 271 from
CTG to CAG. The transfectants were lysed and immunoprecipitated
with the extracellular domain-recognizing antibody or R878
anti-.gamma..sub.c antibodies and Western blotted with JAK-3
antiserum. Expression of transfected wild type and mutant
.gamma..sub.c constructs were similar as determined by flow
cytometry. Note that whereas the extracellular domain-recognizing
antibody mAb bound to an extracellular epitope and thereby all the
mutant forms of .gamma..sub.c tested, R878 cannot bind
.gamma..sub.c-.DELTA.CT or .gamma..sub.c-.DELTA.SH2 truncation
mutants which lack the critical epitope.
[0090] The extracellular domain-recognizing antibody
immunoprecipitates from cells cotransfected with JAK-3 and wild
type .gamma..sub.c contained material that was Western blotted with
anti-JAK-3. No other cotransfectant gave similar results.
Repetition of the procedure using the R878 anti-.gamma..sub.c
immunoprecipitates gave essentially similar results, except that a
small amount of anti-JAK-3 staining material was observed in the
lane corresponding to the lysate from cells that had been
cotransfected with JAK-3 and .gamma..sub.c-L271Q expression
constructs. We noted that the amount of JAK-3 associating with
.gamma..sub.c-L271Q was substantially less than the amount of JAK-3
associating with the wild type .gamma..sub.c. These results
indicated that mutation of the amino acid at position 271 of the
.gamma..sub.c chain inhibited JAK-3 binding. This implicated the
region of the .gamma..sub.c protein that included amino acid
position 271 as being critical for interaction with the JAK-3
protein.
[0091] Neither the vector control nor any of the .gamma..sub.c
mutants that were tested in our experiments gave any indication for
JAK-3 binding. Further, we discovered that the portion of the
.gamma..sub.c chain that included amino acid position 271
represented a critical domain of the protein that was required for
JAK-3 binding.
[0092] We have recently characterized the genetic defect in a
pedigree with an X-linked combined immunodeficiency as a single
nucleotide change within the .gamma..sub.c cytoplasmic domain,
resulting in replacing Leu 271 with Gln. As described above, the
.gamma..sub.c-L271Q mutation significantly diminished but did not
abrogate association with JAK-3. The finding that the
.gamma..sub.c-L271Q mutant still weakly associated with JAK-3 was
consistent with the disease phenotype in this pedigree being less
severe than typical XSCIDs. Nevertheless, affected males manifest
diminished and retarded development of CD4+ and CD8+ T-cells and
decreased T-cell responses to mitogens and IL-2.
[0093] Interestingly, Leu 271 is not contained within the region
deleted in the .gamma..sub.c-.DELTA.SH2 mutant. We interpret this
as indicating that JAK-3 may contact residues both proximal and
distal to the deletion point in the .gamma..sub.c-.DELTA.SH2
construct. An experiment described in Example 15, that was
conducted using a 19 amino acid long peptide spanning Leu 271,
supports this hypothesis since the peptide only partially inhibited
.gamma..sub.c-JAK-3 coprecipitation, even when present at high
molar excess. When IL-2R.beta. and JAK-3 were cotransfected into
COS-7 cells, Mik.beta.1 anti-IL-2R.beta. mAb weakly but
reproducibly coprecipitated JAK-3.
[0094] As described above, we have disclosed that JAK-3 is indeed
the kinase that associates with .gamma..sub.c and that JAK-3 is
activated and tyrosine phosphorylated by all previously known
.gamma..sub.c users tested, as well as IL-9, which we now add to
the list of known .gamma..sub.c users. Moreover, we have partially
defined the regions and residues of .gamma..sub.c required for
JAK-3 association and correlated defective .gamma..sub.c-JAK-3
association with XSCID.
[0095] The activation of JAK-1 by IL-2, IL-4, IL-7, and IL-9 was an
unexpected result and suggests that IL-4R, IL-7R, and IL-9R, like
IL-2R.beta., all associate with JAK-1. We have recently shown that
IL-15 also activates JAK-1 and JAK-3. The activation of JAK-1 and
JAK-3 presumably is vital to signal transduction mediated by IL-2,
IL-4, IL-7, IL-9 and IL-15. However, it is clear that the distinct
signals transduced by different .gamma..sub.c users cannot be
explained solely by JAK-1 and JAK-3. Unique actions, such as the
induction of tyrosine phosphorylation of IRS-1 by IL-4, presumably
play major roles in determining cytokine-specific actions, and may
reflect the abilities of specific receptor complexes to recruit
different substrates for the activated JAKs or other kinases.
[0096] Finally, we contemplate that the discoveries described above
can be used to design assays for identifying compounds that inhibit
IL-2 dependent signaling. Specifically, we contemplate that
compounds that disrupt the interaction between JAK-1 and the
IL-2R.beta. subunit, or between JAK-3 and the .gamma..sub.c subunit
of the IL-2 receptor will be potential inhibitors of IL-2
signalling. The descriptions provided in the foregoing Examples
detail how interactions between the JAK kinases and the IL-2R.beta.
and .gamma..sub.c chains of the receptor can be detected.
Contemplated inhibitors will be identified by virtue of inhibiting
these interactions.
[0097] To illustrate how an inhibitor can be identified according
to the invented method, we have conducted experiments using a
synthetic peptide as a model inhibitor to inhibit the interaction
between .gamma..sub.c and JAK-3 in vitro. Specifically, the peptide
used in this procedure had an amino acid sequence corresponding to
a portion of the .gamma..sub.c chain that binds the JAK-3 protein.
The assay employed standard immunoprecipitation and Western
blotting methods. In the following exemplary case, the
.gamma..sub.c synthetic peptide prevented binding of wild type
.gamma..sub.c to JAK-3. Since the anti-.gamma..sub.c antibody used
in the immunoprecipitation procedure did not immunoprecipitate the
complex between the .gamma..sub.c synthetic peptide and the JAK-3
protein, inhibition of .gamma..sub.c binding to JAK-3 was
determined by virtue of the ability of the synthetic peptide to
inhibit coprecipitation of the complex containing .gamma..sub.c and
JAK-3. Significantly, the fact that a negative control peptide
failed to inhibit the interaction between .gamma..sub.c and JAK-3
demonstrated the specificity of the inhibition. Thus, the assay
described below clearly distinguished between agents that did and
agents that did not inhibit the .gamma..sub.c-JAK-3
interaction.
[0098] Example 15 describes an assay that can be used to identify
compounds that inhibit IL-2 receptor activation by preventing the
interaction between JAK-3 and the .gamma..sub.c chain.
EXAMPLE 15
An Assay for Compounds that Inhibit IL-2 Receptor Complex
Formation
[0099] YT cells or COS-7 cells expressing .gamma..sub.c and JAK-3
were stimulated or not stimulated with IL-2 and then lysed with 10
mM Tris (pH 7.5) containing 2 mM EDTA, 0.15 M NaCl, 0.875% Brij 96,
0.125% NONIDET P40.TM. detergent, 0.4 mM sodium vanadate, 1 mM
4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride (ICN), 2.5
mM leupeptin, 2.5 mM aprotinin. The peptide to be tested as an
inhibitor corresponded to the first 19 amino acids of the
.gamma..sub.c cytoplasmic tail (sequence ERTMPRIPTLKNLEDLVTE) (SEQ
ID NO:7). A negative control peptide that was not expected to
inhibit the interaction between .gamma..sub.c and JAK-3
corresponded to a tyrosine phosphorylated region of .gamma..sub.c.
The negative control peptide had the sequence APPCYTLKPET (SEQ ID
NO:10), and was synthesized so that the Tyr residue at position 5
of the peptide was phosphotyrosine. The test peptide or the
negative control peptide were separately added to the cell lysates
to final concentrations of 140 .mu.M. The positive control
immunoprecipitation was carried out in the absence of added
peptide. Lysates were immunoprecipitated for 16 hours at 4.degree.
C. using antibodies to .gamma..sub.c and protein A sepharose and
washed six times before electrophoresis on SDS gels. The gels were
immunoblotted with antisera to JAK-3 using ECL as described
previously.
[0100] Results of the experiment described above indicated that
only the competitor peptide partially inhibited .gamma..sub.c-JAK-3
coprecipitation. As expected, and consistent with the findings
presented under Example 12, only a weak association between the
.gamma..sub.c and JAK-3 proteins was observed in the absence of
IL-2 stimulation.
[0101] In particular, the lane corresponding to the positive
control coprecipitation in the extracts from IL-2 induced cells
displayed an intense band on the x-ray film at a position
corresponding to a molecular weight of 125 kDa. This result
indicated the position of the JAK-3 protein on the immunoblot and
provided a baseline for quantitative comparison with the test and
negative control samples. The lane corresponding to the negative
control sample had an intensity that was essentially identical to
the band intensity in the positive control lane. This result
indicated that the negative control peptide failed to inhibit
association of .gamma..sub.c and JAK-3 proteins. The lane
corresponding to the sample containing the polypeptide being tested
as an inhibitor had a band representing the JAK-3 protein that was
of significantly diminished intensity. This result indicated that
the 19 amino acid polypeptide having the sequence of SEQ ID NO:6
inhibited the .gamma..sub.c-JAK-3 interaction. These findings
illustrate the results that would be expected in assays for
identifying inhibitors of the .gamma..sub.c-JAK-3 interaction. In
particular, an inhibitor of the y.sub.c-JAK-3 interaction can be
identified by virtue of its ability to lessen the amount of the
.gamma..sub.c-JAK-3 coprecipitate compared to a trial that was
conducted in the absence of any inhibitor.
[0102] Although the foregoing procedure was carried out by first
immunoprecipitating with an anti-.gamma..sub.c antibody and then
Western blotting and probing with an anti-JAK-3 antibody, we
anticipate the order of antibody usage could be reversed with
equally good results. In particular, we anticipate that
immunoprecipitation could be performed using the anti-JAK-3
antibody, and the Western blot probed with the anti-.gamma..sub.c
antibody. In this latter case, inhibitors of the
.gamma..sub.c-JAK-3 interaction would still be identified by virtue
of diminishing the amount of .gamma..sub.c-JAK-3 coprecipitate. The
assay for inhibitors will involve identifying agents that cause a
reduction in the amount of .gamma..sub.c detected on the x-ray film
relative to a trial that omitted the inhibitor.
[0103] Further, we anticipate that assays such as that described
under Example 15 will be useful in the discovery of non-polypeptide
drugs that inhibit the .gamma..sub.c-JAK-3 interaction. These drugs
will similarly be identified in such assays by virtue of their
abilities to inhibit coprecipitation of the .gamma..sub.c-JAK-3
complex.
[0104] Still further, we contemplate coprecipitation and Western
blotting assays to identify compounds that inhibit the interaction
between JAK-1 or JAK-3 and IL-2R.beta.. Such assays can be readily
performed using techniques well known to those having ordinary
skill in the art. Inhibitors of this interaction are believed
useful as drugs to inhibit transmembrane signalling that is
dependent on the interaction between these receptor subunits.
Specifically, these drugs are anticipated for use as
immunomodulators which inhibit IL-2 dependent signalling.
Sequence CWU 1
1
1116PRTArtificial Sequencen-terminal fragment 1Asp Val Trp Ser Phe
Gly1 5228DNAArtificial Sequencesynthetic primer 2ccagcggccg
cgtncaycgn gayctngc 28328DNAArtificial Sequencesynthetic primer
3ccagcggccg cccraanswc canacrtc 2846PRTArtificial
Sequencen-terminal fragment 4Gly Xaa Gly Xaa Xaa Gly1
556PRTArtificial Sequencen-terminal fragment 5Phe Trp Tyr Ala Pro
Glu1 567PRTArtificial Sequencen-terminal fragment 6Val Asp Gly Tyr
Phe Arg Leu1 5719PRTArtificial Sequencen-terminal fragment 7Glu Arg
Thr Met Pro Arg Ile Pro Thr Leu Lys Asn Leu Glu Asp Leu1 5 10 15Val
Thr Glu84064DNAHomo sapiensCDS(96)...(3467) 8ccctctgacc aggactgagg
ggctttttct ctctgtgccc caggcaagtt gcactcatta 60tggaattccg gcggcccgct
aggcaagttg cactc atg gca cct cca agt gaa 113 Met Ala Pro Pro Ser
Glu 1 5gag acg ccc ctg atc cct cag cgt tca tgc agc ctc ttg tcc acg
gag 161Glu Thr Pro Leu Ile Pro Gln Arg Ser Cys Ser Leu Leu Ser Thr
Glu 10 15 20gct ggt gcc ctg cat gtg ctg ctg ccc gct cgg gcc ccg ggg
ccc ccc 209Ala Gly Ala Leu His Val Leu Leu Pro Ala Arg Ala Pro Gly
Pro Pro 25 30 35cag cgc cta tct ttc tcc ttt ggg gac cac ttg gct gag
gac ctg tgc 257Gln Arg Leu Ser Phe Ser Phe Gly Asp His Leu Ala Glu
Asp Leu Cys 40 45 50gtg cag gct gcc aag gcc agc ggc atc ctg cct gtg
tac cac tcc ctc 305Val Gln Ala Ala Lys Ala Ser Gly Ile Leu Pro Val
Tyr His Ser Leu55 60 65 70ttt gct ctg gcc acg gag gac ctg tcc tgc
tgg ttc ccc ccg agc cac 353Phe Ala Leu Ala Thr Glu Asp Leu Ser Cys
Trp Phe Pro Pro Ser His 75 80 85atc ttc tcc gtg gag gat gcc agc acc
caa gtc ctg ctg tac agg att 401Ile Phe Ser Val Glu Asp Ala Ser Thr
Gln Val Leu Leu Tyr Arg Ile 90 95 100cgc ttt tac ttc ccc aat tgg
ttt ggg ctg gag aag tgc cac cgc ttc 449Arg Phe Tyr Phe Pro Asn Trp
Phe Gly Leu Glu Lys Cys His Arg Phe 105 110 115ggg cta cgc aag gat
ttg gcc agt gct atc ctt gac ctg cca gtc ctg 497Gly Leu Arg Lys Asp
Leu Ala Ser Ala Ile Leu Asp Leu Pro Val Leu 120 125 130gag cac ctc
ttt gcc cag cac cgc agt gac ctg gtg agt ggg cgc ctc 545Glu His Leu
Phe Ala Gln His Arg Ser Asp Leu Val Ser Gly Arg Leu135 140 145
150ccc gtg ggc ctc agt ctc aag gag cag ggt gag tgt ctc agc ctg gcc
593Pro Val Gly Leu Ser Leu Lys Glu Gln Gly Glu Cys Leu Ser Leu Ala
155 160 165gtg ttg gac ctg gcc cgg atg gcg cga gag cag gcc cag cgg
ccg gga 641Val Leu Asp Leu Ala Arg Met Ala Arg Glu Gln Ala Gln Arg
Pro Gly 170 175 180gag ctg ctg aag act gtc agc tac aag gcc tgc cta
ccc cca agc ctg 689Glu Leu Leu Lys Thr Val Ser Tyr Lys Ala Cys Leu
Pro Pro Ser Leu 185 190 195cgc gac ctg atc cag ggc ctg agc ttc gtg
acg cgg agg gct att cgg 737Arg Asp Leu Ile Gln Gly Leu Ser Phe Val
Thr Arg Arg Ala Ile Arg 200 205 210agg acg gtg cgc aga gcc ctg ccg
cgc gtg gcc gcc tgc cag gca gac 785Arg Thr Val Arg Arg Ala Leu Pro
Arg Val Ala Ala Cys Gln Ala Asp215 220 225 230cgg cac tcg ctc atg
gcc aag tac atc atg gac ctg gag cgg ctg gat 833Arg His Ser Leu Met
Ala Lys Tyr Ile Met Asp Leu Glu Arg Leu Asp 235 240 245cca gcc ggg
gcc gcc gag acc ttc cac gtg ggc ctc cct ggg gcc ctt 881Pro Ala Gly
Ala Ala Glu Thr Phe His Val Gly Leu Pro Gly Ala Leu 250 255 260ggt
ggc cac gac ggg ctg ggg ctg ctc cgc gtg gct ggt gac ggc ggc 929Gly
Gly His Asp Gly Leu Gly Leu Leu Arg Val Ala Gly Asp Gly Gly 265 270
275atc gcc tgg acc cag gga gaa cag gag gtc ctc cag ccc ttc tgc gac
977Ile Ala Trp Thr Gln Gly Glu Gln Glu Val Leu Gln Pro Phe Cys Asp
280 285 290ttt cca gaa atc gta gac att agc atc aag cag gcc ccg cgc
gtt ggc 1025Phe Pro Glu Ile Val Asp Ile Ser Ile Lys Gln Ala Pro Arg
Val Gly295 300 305 310ccg gcc gga gag cac cgc ctg gtc act gtt acc
agg aca gac aac cag 1073Pro Ala Gly Glu His Arg Leu Val Thr Val Thr
Arg Thr Asp Asn Gln 315 320 325att tta gag gcc gag ttc cca ggg ctg
ccc gag gct ctg tcg ttc gtg 1121Ile Leu Glu Ala Glu Phe Pro Gly Leu
Pro Glu Ala Leu Ser Phe Val 330 335 340gcg ctc gtg gac ggc tac ttc
cgg ctg acc acg gac tcc cag cac ttc 1169Ala Leu Val Asp Gly Tyr Phe
Arg Leu Thr Thr Asp Ser Gln His Phe 345 350 355ttc tgc aag gag gtg
gca ccg ccg agg ctg ctg gag gaa gtg gcc gag 1217Phe Cys Lys Glu Val
Ala Pro Pro Arg Leu Leu Glu Glu Val Ala Glu 360 365 370cag tgc cac
ggc ccc atc act ctg gac ttt gcc atc aac aag ctc aag 1265Gln Cys His
Gly Pro Ile Thr Leu Asp Phe Ala Ile Asn Lys Leu Lys375 380 385
390act ggg ggc tca cgt cct ggc tcc tat gtt ctc cgc cgc agc ccc cag
1313Thr Gly Gly Ser Arg Pro Gly Ser Tyr Val Leu Arg Arg Ser Pro Gln
395 400 405gac ttt gac agc ttc ctc ctc act gtc tgt gtc cag aac ccc
ctt ggt 1361Asp Phe Asp Ser Phe Leu Leu Thr Val Cys Val Gln Asn Pro
Leu Gly 410 415 420cct gat tat aag ggc tgc ctc atc cgg cgc agc ccc
aca gga acc ttc 1409Pro Asp Tyr Lys Gly Cys Leu Ile Arg Arg Ser Pro
Thr Gly Thr Phe 425 430 435ctt ctg gtt ggc ctc agc cga ccc cac agc
agt ctt cga gag ctc ctg 1457Leu Leu Val Gly Leu Ser Arg Pro His Ser
Ser Leu Arg Glu Leu Leu 440 445 450gca acc tgc tgg gat ggg ggg ctg
cac gta gat ggg gtg gca gtg acc 1505Ala Thr Cys Trp Asp Gly Gly Leu
His Val Asp Gly Val Ala Val Thr455 460 465 470ctc act tcc tgc tgt
atc ccc aga ccc aaa gaa aag tcc aac ctg atc 1553Leu Thr Ser Cys Cys
Ile Pro Arg Pro Lys Glu Lys Ser Asn Leu Ile 475 480 485gtg gtc cag
aga ggt cac agc cca ccc aca tca tcc ttg gtt cag ccc 1601Val Val Gln
Arg Gly His Ser Pro Pro Thr Ser Ser Leu Val Gln Pro 490 495 500caa
tcc caa tac cag ctg agt cag atg aca ttt cac aag atc cct gct 1649Gln
Ser Gln Tyr Gln Leu Ser Gln Met Thr Phe His Lys Ile Pro Ala 505 510
515gac agc ctg gag tgg cat gag aac ctg ggc cat ggg tcc ttc acc aag
1697Asp Ser Leu Glu Trp His Glu Asn Leu Gly His Gly Ser Phe Thr Lys
520 525 530att tac cgg ggc tgt cgc cat gag gtg gtg gat ggg gag gcc
cga aag 1745Ile Tyr Arg Gly Cys Arg His Glu Val Val Asp Gly Glu Ala
Arg Lys535 540 545 550aca gag gtg ctg ctg aag gtc atg gat gcc aag
cac aag aac tgc atg 1793Thr Glu Val Leu Leu Lys Val Met Asp Ala Lys
His Lys Asn Cys Met 555 560 565gag tca ttc ctg gaa gca gcg agc ttg
atg agc caa gtg tcg tac cgg 1841Glu Ser Phe Leu Glu Ala Ala Ser Leu
Met Ser Gln Val Ser Tyr Arg 570 575 580cat ctc gtg ctg ctc cac ggc
gtg tgc atg gct gga gac agc acc atg 1889His Leu Val Leu Leu His Gly
Val Cys Met Ala Gly Asp Ser Thr Met 585 590 595gtg cag gaa ttt gta
cac ctg ggg gcc ata gac atg tat ctg cga aaa 1937Val Gln Glu Phe Val
His Leu Gly Ala Ile Asp Met Tyr Leu Arg Lys 600 605 610cgt ggc cac
ctg gtg cca gcc agc tgg aag ctg cag gtg gtc aaa cag 1985Arg Gly His
Leu Val Pro Ala Ser Trp Lys Leu Gln Val Val Lys Gln615 620 625
630ctg gcc tac gcc ctc aac tat ctg gag gac aaa ggc ctg ccc cat ggc
2033Leu Ala Tyr Ala Leu Asn Tyr Leu Glu Asp Lys Gly Leu Pro His Gly
635 640 645aat gtc tct gcc cgg aag gtg ctc ctg gct cgg gag ggg gct
gat ggg 2081Asn Val Ser Ala Arg Lys Val Leu Leu Ala Arg Glu Gly Ala
Asp Gly 650 655 660agc ccg ccc ttc atc aag ctg agt gac cct ggg gtc
agc ccc gct gtg 2129Ser Pro Pro Phe Ile Lys Leu Ser Asp Pro Gly Val
Ser Pro Ala Val 665 670 675tta agc ctg gag atg ctc acc gac agg atc
ccc tgg gtg gcc ccc gag 2177Leu Ser Leu Glu Met Leu Thr Asp Arg Ile
Pro Trp Val Ala Pro Glu 680 685 690tgt ctc cgg gag gcg cag aca ctt
agc ttg gaa gct gac aag tgg ggc 2225Cys Leu Arg Glu Ala Gln Thr Leu
Ser Leu Glu Ala Asp Lys Trp Gly695 700 705 710ttc ggc gcc acg gtc
tgg gaa gtg ttt agt ggc gtc acc atg ccc atc 2273Phe Gly Ala Thr Val
Trp Glu Val Phe Ser Gly Val Thr Met Pro Ile 715 720 725agt gcc ctg
gat cct gct aag aaa ctc caa ttt tat gag gac cgg cag 2321Ser Ala Leu
Asp Pro Ala Lys Lys Leu Gln Phe Tyr Glu Asp Arg Gln 730 735 740cag
ctg ccg gcc ccc aag tgg aca gag ctg gcc ctg ctg att caa cag 2369Gln
Leu Pro Ala Pro Lys Trp Thr Glu Leu Ala Leu Leu Ile Gln Gln 745 750
755tgc atg gcc tat gag ccg gtc cag agg ccc tcc ttc cga gcc gtc att
2417Cys Met Ala Tyr Glu Pro Val Gln Arg Pro Ser Phe Arg Ala Val Ile
760 765 770cgt gac ctc aat agc ctc atc tct tca gac tat gag ctc ctc
tca gac 2465Arg Asp Leu Asn Ser Leu Ile Ser Ser Asp Tyr Glu Leu Leu
Ser Asp775 780 785 790ccc aca cct ggt gcc ctg gca cct cgt gat ggg
ctg tgg aat ggt gcc 2513Pro Thr Pro Gly Ala Leu Ala Pro Arg Asp Gly
Leu Trp Asn Gly Ala 795 800 805cag ctc tat gcc tgc caa gac ccc acg
atc ttc gag gag aga cac ctc 2561Gln Leu Tyr Ala Cys Gln Asp Pro Thr
Ile Phe Glu Glu Arg His Leu 810 815 820aag tac atc tca cag ctg ggc
aag ggc aac ttt ggc agc gtg gag ctg 2609Lys Tyr Ile Ser Gln Leu Gly
Lys Gly Asn Phe Gly Ser Val Glu Leu 825 830 835tgc cgc tat gac ccg
cta gcc cac aat aca ggt gcc ctg gtg gcc gtg 2657Cys Arg Tyr Asp Pro
Leu Ala His Asn Thr Gly Ala Leu Val Ala Val 840 845 850aaa cag ctg
cag cac agc ggg cca gac cag cag agg gac ttt cag cgg 2705Lys Gln Leu
Gln His Ser Gly Pro Asp Gln Gln Arg Asp Phe Gln Arg855 860 865
870gag att cag atc ctc aaa gca ctg cac agt gat ttc att gtc aag tat
2753Glu Ile Gln Ile Leu Lys Ala Leu His Ser Asp Phe Ile Val Lys Tyr
875 880 885cgt ggt gtc agc tat ggc ccg ggc cgg cca gag ctg cgg ctg
gtc atg 2801Arg Gly Val Ser Tyr Gly Pro Gly Arg Pro Glu Leu Arg Leu
Val Met 890 895 900gag tac ctg ccc agc ggc tgc ttg cgc gac ttc ctg
cag cgg cac cgc 2849Glu Tyr Leu Pro Ser Gly Cys Leu Arg Asp Phe Leu
Gln Arg His Arg 905 910 915gcg cgc ctc gat gcc agc cgc ctc ctt ctc
tat tcc tcg cag atc tgc 2897Ala Arg Leu Asp Ala Ser Arg Leu Leu Leu
Tyr Ser Ser Gln Ile Cys 920 925 930aag ggc atg gag tac ctg ggc tcc
cgc cgc tgc gtg cac cgc gac ctg 2945Lys Gly Met Glu Tyr Leu Gly Ser
Arg Arg Cys Val His Arg Asp Leu935 940 945 950gcc gcc cga aac atc
ctc gtg gag agc gag gca cac gtc aag atc gct 2993Ala Ala Arg Asn Ile
Leu Val Glu Ser Glu Ala His Val Lys Ile Ala 955 960 965gac ttc ggc
cta gct aag ctg ctg ccg ctt gac aaa gac tac tac gtg 3041Asp Phe Gly
Leu Ala Lys Leu Leu Pro Leu Asp Lys Asp Tyr Tyr Val 970 975 980gtc
cgc gag cca ggc cag agc ccc att ttc tgg tat gcc ccc gaa tcc 3089Val
Arg Glu Pro Gly Gln Ser Pro Ile Phe Trp Tyr Ala Pro Glu Ser 985 990
995ctc tcg gac aac atc ttc tct cgc cag tca gac gtc tgg agc ttc ggg
3137Leu Ser Asp Asn Ile Phe Ser Arg Gln Ser Asp Val Trp Ser Phe Gly
1000 1005 1010gtc gtc ctg tac gag ctc ttc acc tac tgc gac aaa agc
tgc agc ccc 3185Val Val Leu Tyr Glu Leu Phe Thr Tyr Cys Asp Lys Ser
Cys Ser Pro1015 1020 1025 1030tcg gcc gag ttc ctg cgg atg atg gga
tgt gag cgg gat gtc ccc gcc 3233Ser Ala Glu Phe Leu Arg Met Met Gly
Cys Glu Arg Asp Val Pro Ala 1035 1040 1045ctc tgc cgc ctc ttg gaa
ctg ctg gag gag ggc cag agg ctg ccg gcg 3281Leu Cys Arg Leu Leu Glu
Leu Leu Glu Glu Gly Gln Arg Leu Pro Ala 1050 1055 1060cct cct gcc
tgc cct gct gag gtt cac gag ctc atg aag ctg tgc tgg 3329Pro Pro Ala
Cys Pro Ala Glu Val His Glu Leu Met Lys Leu Cys Trp 1065 1070
1075gcc cct agc cca cag gac cgg cca tca ttc agc gcc ctg ggc ccc cag
3377Ala Pro Ser Pro Gln Asp Arg Pro Ser Phe Ser Ala Leu Gly Pro Gln
1080 1085 1090ctg gac atg ctg tgg agc gga agc cgg ggg tgt gag act
cat gcc ttc 3425Leu Asp Met Leu Trp Ser Gly Ser Arg Gly Cys Glu Thr
His Ala Phe1095 1100 1105 1110act gct cac cca gag ggc aaa cac cac
tcc ctg tcc ttt tca 3467Thr Ala His Pro Glu Gly Lys His His Ser Leu
Ser Phe Ser 1115 1120tagctcctgc ccgcagacct ctggattagg tctctgttga
ctggctgtgt gaccttaggc 3527ccggagctgc ccctctctgg gcctcagagg
ccttatgagg gtcctctact tcaggaacac 3587ccccatgaca ttgcatttgg
gggggctccc gtggcctgta gaatagcctg tggcctttgc 3647aatttgttaa
ggttcaagac agatgggcat atgtgtcagt ggggctctct gagtcctggc
3707ccaaagaagc aaggaaccaa atttaagact ctcgcatctt cccaacccct
taagccctgg 3767ccccctgagt ttccttttct cgtctctctc tttttatttt
ttttattttt atttttattt 3827ttgagacaga gcctcgctcg ttacccaggg
tggagtgcag tggtagcgat ctcggctcac 3887agtgcaacct ctgcttccca
ggttcaagcg attctcctgc ctcagcctcc cgagtagctg 3947ggattacagg
tgtgcaccac cacacccggc taattttttt tatttttaat agagatgagg
4007tttcaccatg atggccaggc tgatctcgaa ctcctaacct caagtgatcc tcccacc
406491124PRTHomo sapiens 9Met Ala Pro Pro Ser Glu Glu Thr Pro Leu
Ile Pro Gln Arg Ser Cys1 5 10 15Ser Leu Leu Ser Thr Glu Ala Gly Ala
Leu His Val Leu Leu Pro Ala 20 25 30Arg Ala Pro Gly Pro Pro Gln Arg
Leu Ser Phe Ser Phe Gly Asp His 35 40 45Leu Ala Glu Asp Leu Cys Val
Gln Ala Ala Lys Ala Ser Gly Ile Leu 50 55 60Pro Val Tyr His Ser Leu
Phe Ala Leu Ala Thr Glu Asp Leu Ser Cys65 70 75 80Trp Phe Pro Pro
Ser His Ile Phe Ser Val Glu Asp Ala Ser Thr Gln 85 90 95Val Leu Leu
Tyr Arg Ile Arg Phe Tyr Phe Pro Asn Trp Phe Gly Leu 100 105 110Glu
Lys Cys His Arg Phe Gly Leu Arg Lys Asp Leu Ala Ser Ala Ile 115 120
125Leu Asp Leu Pro Val Leu Glu His Leu Phe Ala Gln His Arg Ser Asp
130 135 140Leu Val Ser Gly Arg Leu Pro Val Gly Leu Ser Leu Lys Glu
Gln Gly145 150 155 160Glu Cys Leu Ser Leu Ala Val Leu Asp Leu Ala
Arg Met Ala Arg Glu 165 170 175Gln Ala Gln Arg Pro Gly Glu Leu Leu
Lys Thr Val Ser Tyr Lys Ala 180 185 190Cys Leu Pro Pro Ser Leu Arg
Asp Leu Ile Gln Gly Leu Ser Phe Val 195 200 205Thr Arg Arg Ala Ile
Arg Arg Thr Val Arg Arg Ala Leu Pro Arg Val 210 215 220Ala Ala Cys
Gln Ala Asp Arg His Ser Leu Met Ala Lys Tyr Ile Met225 230 235
240Asp Leu Glu Arg Leu Asp Pro Ala Gly Ala Ala Glu Thr Phe His Val
245 250 255Gly Leu Pro Gly Ala Leu Gly Gly His Asp Gly Leu Gly Leu
Leu Arg 260 265 270Val Ala Gly Asp Gly Gly Ile Ala Trp Thr Gln Gly
Glu Gln Glu Val 275 280 285Leu Gln Pro Phe Cys Asp Phe Pro Glu Ile
Val Asp Ile Ser Ile Lys 290 295 300Gln Ala Pro Arg Val Gly Pro Ala
Gly Glu His Arg Leu Val Thr Val305 310 315 320Thr Arg Thr Asp Asn
Gln Ile Leu Glu Ala Glu Phe Pro Gly Leu Pro 325 330 335Glu Ala Leu
Ser Phe Val Ala Leu Val Asp Gly Tyr Phe Arg Leu Thr 340 345 350Thr
Asp Ser Gln His Phe Phe Cys Lys Glu Val Ala Pro Pro Arg Leu 355 360
365Leu Glu Glu Val Ala Glu Gln Cys His Gly Pro Ile Thr Leu Asp Phe
370 375 380Ala Ile Asn Lys Leu Lys Thr Gly Gly Ser Arg Pro Gly Ser
Tyr Val385 390 395 400Leu Arg Arg Ser Pro Gln Asp Phe Asp Ser Phe
Leu Leu Thr Val Cys 405 410 415Val Gln Asn Pro Leu Gly Pro Asp Tyr
Lys Gly Cys Leu Ile Arg Arg 420 425
430Ser Pro Thr Gly Thr Phe Leu Leu Val Gly Leu Ser Arg Pro His Ser
435 440 445Ser Leu Arg Glu Leu Leu Ala Thr Cys Trp Asp Gly Gly Leu
His Val 450 455 460Asp Gly Val Ala Val Thr Leu Thr Ser Cys Cys Ile
Pro Arg Pro Lys465 470 475 480Glu Lys Ser Asn Leu Ile Val Val Gln
Arg Gly His Ser Pro Pro Thr 485 490 495Ser Ser Leu Val Gln Pro Gln
Ser Gln Tyr Gln Leu Ser Gln Met Thr 500 505 510Phe His Lys Ile Pro
Ala Asp Ser Leu Glu Trp His Glu Asn Leu Gly 515 520 525His Gly Ser
Phe Thr Lys Ile Tyr Arg Gly Cys Arg His Glu Val Val 530 535 540Asp
Gly Glu Ala Arg Lys Thr Glu Val Leu Leu Lys Val Met Asp Ala545 550
555 560Lys His Lys Asn Cys Met Glu Ser Phe Leu Glu Ala Ala Ser Leu
Met 565 570 575Ser Gln Val Ser Tyr Arg His Leu Val Leu Leu His Gly
Val Cys Met 580 585 590Ala Gly Asp Ser Thr Met Val Gln Glu Phe Val
His Leu Gly Ala Ile 595 600 605Asp Met Tyr Leu Arg Lys Arg Gly His
Leu Val Pro Ala Ser Trp Lys 610 615 620Leu Gln Val Val Lys Gln Leu
Ala Tyr Ala Leu Asn Tyr Leu Glu Asp625 630 635 640Lys Gly Leu Pro
His Gly Asn Val Ser Ala Arg Lys Val Leu Leu Ala 645 650 655Arg Glu
Gly Ala Asp Gly Ser Pro Pro Phe Ile Lys Leu Ser Asp Pro 660 665
670Gly Val Ser Pro Ala Val Leu Ser Leu Glu Met Leu Thr Asp Arg Ile
675 680 685Pro Trp Val Ala Pro Glu Cys Leu Arg Glu Ala Gln Thr Leu
Ser Leu 690 695 700Glu Ala Asp Lys Trp Gly Phe Gly Ala Thr Val Trp
Glu Val Phe Ser705 710 715 720Gly Val Thr Met Pro Ile Ser Ala Leu
Asp Pro Ala Lys Lys Leu Gln 725 730 735Phe Tyr Glu Asp Arg Gln Gln
Leu Pro Ala Pro Lys Trp Thr Glu Leu 740 745 750Ala Leu Leu Ile Gln
Gln Cys Met Ala Tyr Glu Pro Val Gln Arg Pro 755 760 765Ser Phe Arg
Ala Val Ile Arg Asp Leu Asn Ser Leu Ile Ser Ser Asp 770 775 780Tyr
Glu Leu Leu Ser Asp Pro Thr Pro Gly Ala Leu Ala Pro Arg Asp785 790
795 800Gly Leu Trp Asn Gly Ala Gln Leu Tyr Ala Cys Gln Asp Pro Thr
Ile 805 810 815Phe Glu Glu Arg His Leu Lys Tyr Ile Ser Gln Leu Gly
Lys Gly Asn 820 825 830Phe Gly Ser Val Glu Leu Cys Arg Tyr Asp Pro
Leu Ala His Asn Thr 835 840 845Gly Ala Leu Val Ala Val Lys Gln Leu
Gln His Ser Gly Pro Asp Gln 850 855 860Gln Arg Asp Phe Gln Arg Glu
Ile Gln Ile Leu Lys Ala Leu His Ser865 870 875 880Asp Phe Ile Val
Lys Tyr Arg Gly Val Ser Tyr Gly Pro Gly Arg Pro 885 890 895Glu Leu
Arg Leu Val Met Glu Tyr Leu Pro Ser Gly Cys Leu Arg Asp 900 905
910Phe Leu Gln Arg His Arg Ala Arg Leu Asp Ala Ser Arg Leu Leu Leu
915 920 925Tyr Ser Ser Gln Ile Cys Lys Gly Met Glu Tyr Leu Gly Ser
Arg Arg 930 935 940Cys Val His Arg Asp Leu Ala Ala Arg Asn Ile Leu
Val Glu Ser Glu945 950 955 960Ala His Val Lys Ile Ala Asp Phe Gly
Leu Ala Lys Leu Leu Pro Leu 965 970 975Asp Lys Asp Tyr Tyr Val Val
Arg Glu Pro Gly Gln Ser Pro Ile Phe 980 985 990Trp Tyr Ala Pro Glu
Ser Leu Ser Asp Asn Ile Phe Ser Arg Gln Ser 995 1000 1005Asp Val
Trp Ser Phe Gly Val Val Leu Tyr Glu Leu Phe Thr Tyr Cys 1010 1015
1020Asp Lys Ser Cys Ser Pro Ser Ala Glu Phe Leu Arg Met Met Gly
Cys1025 1030 1035 1040Glu Arg Asp Val Pro Ala Leu Cys Arg Leu Leu
Glu Leu Leu Glu Glu 1045 1050 1055Gly Gln Arg Leu Pro Ala Pro Pro
Ala Cys Pro Ala Glu Val His Glu 1060 1065 1070Leu Met Lys Leu Cys
Trp Ala Pro Ser Pro Gln Asp Arg Pro Ser Phe 1075 1080 1085Ser Ala
Leu Gly Pro Gln Leu Asp Met Leu Trp Ser Gly Ser Arg Gly 1090 1095
1100Cys Glu Thr His Ala Phe Thr Ala His Pro Glu Gly Lys His His
Ser1105 1110 1115 1120Leu Ser Phe Ser1011PRTArtificial
Sequencen-terminal fragment 10Ala Pro Pro Cys Tyr Thr Leu Lys Pro
Glu Thr1 5 101121PRTArtificial Sequencesynthetic peptide 11Gly Cys
Glu Thr His Ala Phe Thr Ala His Pro Glu Gly Lys His His1 5 10 15Ser
Leu Ser Phe Ser 20
* * * * *